Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Chenodiol

Chenodiol: 2 brands, 1 generic; first approved Jul 28, 1983; generic available.

Generic available2 exclusivity periodsHas discontinued products
Generic status & protection

Generic available: 1 ANDA application approved.

Latest exclusivity ends
Brands (NDA)
2
Generics (ANDA)
1
Listed patents
0
Presentations
3

Brand (NDA) products

Originator applications
  • CTEXLIRLDRS
    NDA 2194882025
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    250MGTABLETORALRx
  • NDA 0185131983
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    250MGTABLETORALDiscontinued

Generic (ANDA) products (1)

Abbreviated applications
  • CHENODIOLRS
    ANDA 0910192009
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    250MGTABLETORALRx

Patent & exclusivity timeline

Protection horizon
20262027202820292030203120322033TodayExclusivity NP: 2028-02-21Exclusivity NPExclusivity ODE-523: 2032-02-21Exclusivity ODE-523
Patent expiryExclusivity endToday

Marketing exclusivity

Hatch-Waxman
  • NPNew product exclusivity (3 years)

    in 1 yr 6 mo

  • ODE-523Orphan-drug exclusivity (7 years)

    in 5 yr 7 mo

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
43 yr 8 mo ago
Most recent approval
1 yr 6 mo ago

Approvals span 1983–2025 across 3 FDA applications.

Brand (NDA) 267%
Generic (ANDA) 133%

Chenodiol: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.